We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Lotion) in the Relief of Sunburn Related Symptoms

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2009 by Mantecorp Industria Quimica e Farmaceutica Ltd..
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01085851
First Posted: March 12, 2010
Last Update Posted: March 12, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Mantecorp Industria Quimica e Farmaceutica Ltd.
  Purpose
Topical antihistamines can be used to promote relief of sunburn related symptoms (erythema, itch and burning sensations). Dexchlorpheniramine maleate 1% cream is a topical antihistamine formulation approved by ANVISA in Brazil for the relief of skin irritation and pruritus, including the ones caused by sunburn. The aim of the present study is to demonstrate non-inferiority of a new pharmacological preparation of dexchlorpheniramine maleate (1% lotion) with the standard preparation (1% cream) for the relief of sunburn related symptoms and to demonstrate the safety of both preparations.

Condition Intervention Phase
Sunburn Drug: Dexchlorpheniramine 1% lotion Drug: Dexchlorpheniramine 1% cream Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Non-inferiority, Monocentric Comparative Open Study of Two Topical Pharmaceutical Preparations (Cream and Lotion) of Dexchlorpheniramine Maleate in the Evaluation of Safety and Efficacy for the Relief of Sunburn Related Symptoms

Resource links provided by NLM:


Further study details as provided by Mantecorp Industria Quimica e Farmaceutica Ltd.:

Primary Outcome Measures:
  • Pruritus intensity evaluated with a 10-point Visual Analogic Scale (VAS) [ Time Frame: 7 days ]

Secondary Outcome Measures:
  • Composite clinical evaluation of erythema, pruritus and burning sensation performed by the investigator using a 4-point scale for each one of the variables (absent, mild, moderate, intense). [ Time Frame: 7 days ]

Estimated Enrollment: 30
Arms Assigned Interventions
Experimental: Dexchlorpheniramine 1% lotion Drug: Dexchlorpheniramine 1% lotion
Small amount applied over the lesion twice a day for 7 days
Active Comparator: Dexchlorpheniramine 1% cream Drug: Dexchlorpheniramine 1% cream
Small amount applied over the lesion twice a day for 7 days

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signs of solar erythema of mild to moderate intensity resulting from voluntary exposure to sun within the last 72 hours
  • Presence of lesions with some degree of symmetry to allow comparison between both pharmaceutical formulations
  • Compliance of the subject to the treatment protocol
  • Agreement with the terms of the informed consent by the participants or their legal guardians when younger than 18 years old

Exclusion Criteria:

  • Pregnancy or risk of pregnancy
  • Lactation
  • Signs of solar erythema of severe intensity
  • Use of topical or systemic anti-inflammatory, antihistamine or immunosuppressive drugs within the last 48 hours prior to the study
  • History of atopy or allergic diseases
  • History of allergy to any component of the formulations
  • Other conditions considered by the investigator as reasonable for non-eligibility
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01085851


Contacts
Contact: Sérgio Schalka, MD +551136811334

Locations
Brazil
Medcin Instituto da Pele Ltda Not yet recruiting
São Paulo, SP, Brazil
Contact: Patrícia C Pinto         
Sponsors and Collaborators
Mantecorp Industria Quimica e Farmaceutica Ltd.
Investigators
Principal Investigator: Sérgio Schalka, MD Medcin Instituto da Pele Ltda
  More Information

Responsible Party: Celso Pereira Sustovich, Medical Director, Mantecorp Industria Quimica e Farmaceutica Ltd.
ClinicalTrials.gov Identifier: NCT01085851     History of Changes
Other Study ID Numbers: ERE 976-08
First Submitted: March 11, 2010
First Posted: March 12, 2010
Last Update Posted: March 12, 2010
Last Verified: October 2009

Keywords provided by Mantecorp Industria Quimica e Farmaceutica Ltd.:
Sunburn
Dexchlorpheniramine
Lotion
Cream

Additional relevant MeSH terms:
Sunburn
Photosensitivity Disorders
Skin Diseases
Burns
Wounds and Injuries
Dexchlorpheniramine
Chlorpheniramine
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipruritics
Dermatologic Agents
Anti-Allergic Agents